Literature DB >> 25113167

Activity-dependent alterations in the sensitivity to BDNF-TrkB signaling may promote excessive dendritic arborization and spinogenesis in fragile X syndrome in order to compensate for compromised postsynaptic activity.

Sang Woo Kim1, Kyoung Joo Cho2.   

Abstract

Fragile X syndrome (FXS), the most common cause of inherited human mental retardation, results from the loss of function of fragile X mental retardation protein (FMRP). To date, most researchers have thought that FXS neural pathologies are primarily caused by extreme dendritic branching and spine formation. With this rationale, several researchers attempted to prune dendritic branches and reduce the number of spines in FXS animal models. We propose that increased dendritic arborization and spinogenesis in FXS are developed rather as secondary compensatory responses to counteract the compromised postsynaptic activity during uncontrollable metabotropic glutamate receptor (mGluR)-dependent long-term depression (LTD). When postsynaptic and electrical activities become dampened in FXS, dendritic trees can increase their sensitivity to brain-derived neurotrophic factor (BDNF) by using the molecular sensor called eukaryotic elongation factor 2 (eEF2) and taking advantage of the tight coupling of mGluR and BDNF-TrkB signaling pathways. Then, this activity-dependent elevation of the BDNF signaling can strategically alter dendritic morphologies to foster branching and develop spine structures in order to improve the postsynaptic response in FXS. Our model suggests a new therapeutic rationale for FXS: correcting the postsynaptic and electrical activity first, and then repairing structural abnormalities of dendrites. Then, it may be possible to successfully fix the dendritic morphologies without affecting the survival of neurons. Our theory may also be generalized to explain aberrant dendritic structures observed in other neurobehavioral diseases, such as tuberous sclerosis, Rett syndrome, schizophrenia, and channelopathies, which accompany high postsynaptic and electrical activity.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25113167     DOI: 10.1016/j.mehy.2014.07.007

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  6 in total

Review 1.  Dendrite and spine modifications in autism and related neurodevelopmental disorders in patients and animal models.

Authors:  Verónica Martínez-Cerdeño
Journal:  Dev Neurobiol       Date:  2016-08-30       Impact factor: 3.964

Review 2.  Adaptive control of synaptic plasticity integrates micro- and macroscopic network function.

Authors:  Daniel N Scott; Michael J Frank
Journal:  Neuropsychopharmacology       Date:  2022-08-29       Impact factor: 8.294

Review 3.  Synaptic Plasticity, a Prominent Contributor to the Anxiety in Fragile X Syndrome.

Authors:  Tao Yang; Huan Zhao; Changbo Lu; Xiaoyu Li; Yingli Xie; Hao Fu; Hui Xu
Journal:  Neural Plast       Date:  2016-04-28       Impact factor: 3.599

4.  BDNF and NGF Signalling in Early Phases of Psychosis: Relationship With Inflammation and Response to Antipsychotics After 1 Year.

Authors:  M Martinez-Cengotitabengoa; K S MacDowell; S Alberich; F J Diaz; B Garcia-Bueno; R Rodriguez-Jimenez; M Bioque; E Berrocoso; M Parellada; A Lobo; P A Saiz; C Matute; M Bernardo; A Gonzalez-Pinto; J C Leza
Journal:  Schizophr Bull       Date:  2015-06-30       Impact factor: 9.306

Review 5.  Fragile X targeted pharmacotherapy: lessons learned and future directions.

Authors:  Craig A Erickson; Matthew H Davenport; Tori L Schaefer; Logan K Wink; Ernest V Pedapati; John A Sweeney; Sarah E Fitzpatrick; W Ted Brown; Dejan Budimirovic; Randi J Hagerman; David Hessl; Walter E Kaufmann; Elizabeth Berry-Kravis
Journal:  J Neurodev Disord       Date:  2017-06-12       Impact factor: 4.025

Review 6.  Molecular Biomarkers in Fragile X Syndrome.

Authors:  Marwa Zafarullah; Flora Tassone
Journal:  Brain Sci       Date:  2019-04-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.